Pretreatment with fragments of substance-P or with cholecystokinin differentially affects recovery from sub-total nigrostriatal 6-hydroxydopamine lesion

Neural Plasticity

Volumn 6, Issue 4, 1999, Pages 77-89

  Nikolaus, S ^a   Huston, J P ^a   Schwarting, R K W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; DOPAMINE; NEUROPEPTIDE; OXIDOPAMINE; SUBSTANCE P;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROCHEMISTRY; NONHUMAN; RAT; SUBSTANTIA NIGRA;

EID: 0032721190     PISSN: 20905904     EISSN: None     Source Type: Journal    
DOI: 10.1155/NP.1999.77     Document Type: Article

References (41)

1. Banks WA, Kastin AJ. Saturable transport of peptides across the blood-brain barrier. Life Sciences 1987; 41: 1319-1338.
2. Bannon MJ, Brownschidle LA, Tian Y, Whitty CJ, Poosch MS, D'sa C, Moody CA. Neurokinin-3 receptors modulate dopamine cell function and alter the effects of 6-hydroxydopamine. Brain Res 1995; 695: 19-24.
3. Barker R. Substance P and Parkinson's disease: A causal relationship? J Theor Biol 1986; 120: 353-362.
4. Barker R. Substance P. and neurodegenerative disorders. A speculative review. Neuropeptides 1991; 20: 73-78.
5. Bea AJ, Elde R, Oellig C, Cao Y, Pettersson RF, Hökfelt T. Acidic and basic fibroblast growth factors are present in and produce effects upon mesencephalic dopamine neurons. In: Fuxe K, Agnati LF, Bjelke B, Ottoson D, eds., Trophic Regulation of the Basal Ganglia. Pergamon Press, 1994; 267-284.
6. Boix F, Huston JP, Schwarting RKW. The C-terminal fragment of substance P enhances dopamine release in nucleus accumbens but not in the neostriatum in freely moving rats. Brain Res 1992a; 592: 181-186.
7. Boix F, Mattioli R, Adams F, Huston JP, Schwarting RKW. Effects of substance P on extracellular dopamine in neostriatum and nucleus accumbens. Eur J Pharmacol 1992b; 216: 103-107.
8. Boix F, Sandor P, Nogueira PJC, Huston JP, Schwarting RKW. Relationship between dopamine release in nucleus accumbens and place preference induced by substance P injected into the nucleus basalis magnocellularis region. Neuroscience 1995; 64: 1045-1055.
9. DiChiara G, Imperato A, Mulas A. Preferential stimulation of dopamine release in the mesolimbic system: a common feature of drugs of abuse. In: Sandler M, Feuerstein C, Scatton B, eds, Neurotransmitter Interactions in the Basal Ganglia. New York: Raven Press, 1987; 171-182.
10. Emmi A, Rajabi H, Stewart J. Behavioral and neurochemical recovery from partial 6-hydroxy-dopamine lesions of the substantia nigra is blocked by daily treatment with glutamate receptor antagonists MK-801 and CPP. J Neurosci 1994; 16: 5216-5224.
11. Fibiger HC, Phillips AG. Mesocorticolimbic dopamine systems and reward. Ann NY Acad Sci 1988; 537: 206-215.
12. Fornaguera J, Carey RJ, Huston JP, Schwarting RKW. Behavioral asymmetries and recovery in rats with different degrees of unilateral striatal dopamine depletion. Brain Res 1994; 664: 178.
13. Fujisawa M, Miyamoto O, Itano T, Tokuda M, Matsui H, Nagao S, Negi T, Hatase O. Ceruletide suppresses rotational behavior in lesioned rats via CCKA receptors. Europ J Pharmacol 1993; 238: 127-130.
14. Gerhardt P, Voits M, Fink H, Huston JP. Evidence for mnemotropic action of cholecystokinin fragments Boc-CCK-4 and CCK-8S. Peptides 1994; 15: 689-697.
15. Hasenöhrl RU, Frisch C, Nikolaus S, Huston JP. Chronic administration of neurokinin SP improves maze performance in aged Rattus norvegicus. Behav Neural Biol 1994; 62: 110-120.
16. Huston JP, Morgan S, Steiner H. Plasticity in crossed efferents to the substantia nigra as related to behavioral reorganization. In: Schneider JS, Lidsky TI, eds., Basal Ganglia and Behavior: Sensory Aspects of Motor Functioning. Bern: Huber, 1987, 89-102.
17. Huston JP, Hasenöhrl RU, Boix F, Gerhardt P, Schwarting RKW. Sequence-specific effects of neurokinin substance P on memory, reinforce-ment, and brain dopamine activity. Psycho-pharmacology 1993; 112: 147-162.
18. Huston JP, Hasenöhrl RU. The role of neuro-peptides in learning: focus on the neurokinin substance P. Behav Brain Res 1995; 66: 117-127.
19. Jonsson G, Hallmann H. Substance P counteracts neurotoxic damage on norepine-phrine neurons in rat brain during ontogeny. Science 1982a; 215: 75-77.
20. Jonsson G, Hallman H. Substance P modifies the 6-hydroxydopamine induced alteration of post-natal development of central noradrenal-ine neurons. Neuroscience 1982b; 7: 2909-2918.
21. Katsuura G, Shinohara S, Shintaku H, Eigyo M, Matusushita A. Protective effect of CCK-8 and ceruletide on glutamate-induced neuronal cell death in rat neuron cultures: possible involvement of CCK-B receptors. Neurosci Lett 1991; 132: 159-162.
22. Khan S, Brooks N, Whelpton R, Michael-Titus AT. Substance P-(1-7) and substance P-(5-11) locally modulate dopamine release in rat striatum. Eur J Pharmacol 1995; 282: 229-233.
23. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242: 715-723.
24. Lindner G, Grosse G, Oehme P, Jentzsch KD, Neubert K. Über die Wirkung von Substanz P (SP) und SP-Teilsequenzen auf das Nervenfaser-wachstum in der Gewebekultur. Z mikrosk anat Forsch 1982; 96: 643-655.
25. Lindner G, Gadewa S. Über die Wirkung von N-und C-terminalen Sequenzen der Substanz P auf nicht-neuronale Zellen in vitro (Nervenge-webekultur). Z mikrosk anat Forsch 1984; 98: 107-118.
26. Mattioli R, Schwarting RKW, Huston JP. Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P1-11. Neuroscience 1992; 48: 595-605.
27. Narumi S, Maki Y. Stimulatory effects of substance P on neurite extension and cyclic AMP levels in cultured neuroblastoma cells. J Neurochem 1978; 30: 1321-1326.
28. Nikolaus S, Huston JP, Körber B, Thiel C, Schwarting RKW. Pre-treatment with neurokinin substance P but not with cholecystokinin-8S can alleviate functional deficits of partial nigrostriatal 6-hydroxydopamine lesion. Peptides 1997; 18:
29. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sidney: Academic Press, 1986.
30. Payan DG.The role of neuropeptides in inflam-mation. In: Gallin JI, Goldstein IM, Snyderman R, eds, Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, 1992; 177.
31. Pernow B. Substance P. Pharmacol Rev 1983; 35: 85-141.
32. Reid MS, Herrera-Marschitz M, Hökfelt T, Lindefors N, Persson H, Ungerstedt U. Striato-nigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopa-mine release: evidence for direct regulatory mechanisms. Exp Brain Res 1990; 82: 293-303.
33. Schwarting RKW, Goldenberg R, Steiner H, Fornaguera J, Huston JP. A video-image analyzing system for open-field behavior in the rat focusing on behavioral asymmetries. J Neurosci Meth 1993; 49: 199-210.
34. Schwarting RKW, Huston JP. Unilateral 6-hydroxydopamine lesions of mesostriatal dopamine neurons and their physiological sequelae. Progr Neurobiol 1996a; 49: 215-266.
35. Schwarting RKW, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996b; 50: 275-331.
36. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxy-dopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system. J Neurochem 1992; 59: 99-105.
37. Stromberg I, Herrera-Marschitz M, Ungerstedt U, Ebendal T, Olson L. Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior. Exp Brain Res 1985; 60: 335-349.
38. Tamura Y, Sato Y, Akaike A, Shiomi, H. Mechanisms of cholecystokinin-induced pro-tection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated gluta-mate cytotoxicity. Brain Res 1992; 592: 317-325.
39. White DM, Ehrhard P, Hardung M, Meyer KD, Zimmermann M, Otten U. Substance P modulates the release of locally synthesized nerve growth factor from rat saphenous nerve neuroma. Naunyn-Schmiedeberg's Arch Pharmacol 1987; 336: 587-590.
40. Whitty CJ, Kapatos G, Bannon MJ. Neurotrophic effects of substance P on hippocampal neurons in vitro. Neurosci Lett 1993; 164: 141-144.
41. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990; 250: 279-282.